Abstract
Background/Aims: Contributions to the understanding of acute renal failure (ARF) pathogenesis have not been translated into an effective clinical therapy. We studied the effects of pretreatment with the angiotensin II type 1 (AT1) receptor blocker, losartan, on renal function, tissue injury, inflammatory response and serum aldosterone levels in a model of ischemic ARF. Methods: Rats underwent unilateral renal ischemia followed by 24 h of reperfusion (IR), and were pretreated or not with 8 (IRL8) or 80 (IRL80) mg/kg/day of losartan for 3 days. Results: IR kidneys showed marked renal dysfunction, epithelial damage, capillary congestion, increased myeloperoxidase (MPO) activity and increased TNF-α, IL1-β and IL-6 mRNA levels. IRL80 kidneys showed protection against dysfunction and tissue injury, associated with normal MPO activity and cytokine mRNA levels. The lower dose was not able to achieve the same degree of functional renoprotection and could not prevent an increase of MPO or proinflammatory cytokine mRNA levels. The high losartan dose completely prevented an increase of serum aldosterone levels induced by IR. Conclusion: Renoprotection of the high losartan dose would be mainly mediated by its anti-inflammatory actions. Our results show a potential pathophysiological role of AT1 activation in promoting renal dysfunction, structural injury, inflammation and aldosterone elevation after IR injury.
Journal Section:
Original Paper
References
1.
Shoskes DA, Halloran PF: Delayed graft function in renal transplantation: etiology, management and long-term significance. J Urol 1996;155:1831–1840.
[PubMed]
2.
Kelly KJ, Molitoris BA: Acute renal failure in the new millennium: time to consider combination therapy. Semin Nephrol 2000;20:4–19.
[PubMed]
3.
Bonventre JV, Weinberg JM: Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 2003;14:2199–2210.
[PubMed]
4.
Bonventre JV, Zuk A: Ischemic acute renal failure: an inflammatory disease? Kidney Int 2004;66:480–485.
[PubMed]
5.
Daha MR, van Kooten C: Is the proximal tubular cell a proinflammatory cell? Nephrol Dial Transplant 2000;15(suppl 6):41–43.
[PubMed]
6.
Ruiz-Ortega M, Ruperez M, Esteban V, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J: Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 2006;21:16–20.
[PubMed]
7.
Harrison-Bernard LM, Navar LG, Ho MM, Vinson GP, el-Dahr SS: Immunohistochemical localization of ANGII AT1 receptor in adult rat kidney using a monoclonal antibody. Am J Physiol 1997;273:F170–F177.
[PubMed]
8.
Cheng ZJ, Vapaatalo H, Mervaala E: Angiotensin II and vascular inflammation. Med Sci Monit 2005;11:194–205.
9.
Grafe M, Auch-Schwelk W, Zakrzewicz A, Regitz-Zagrosek V, Bartsch P, Graf K, Loebe M, Gaehtgens P, Fleck E: Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ Res 1997;81:804–811.
[PubMed]
10.
Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, Egido J: Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int 2002;62:S12–S22.
11.
Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ: Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006;1:256–262.
[PubMed]
12.
Zhou X, Ono H, Ono Y, Frohlich ED: Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Am J Nephrol 2004;24:242–249.
[PubMed]
13.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.
[PubMed]
14.
Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73–87.
[PubMed]
15.
Goncalves AR, Fujihara CK, Mattar AL, Malheiros DM, Noronha Ide L, de Nucci G, Zatz R: Renal expression of COX-2, ANGII, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a non-steroidal anti-inflammatory. Am J Physiol Renal Physiol 2004;286:F945–F954.
[PubMed]
16.
Allred AJ, Chappell MC, Ferrario CM, Diz DI: Differential actions of renal ischemic injury on the intrarenal angiotensin system. Am J Physiol Renal Physiol 2000;279:F636–F645.
[PubMed]
17.
Kontogiannis J, Burns KD: Role of AT1 angiotensin II receptors in renal ischemic injury. Am J Physiol 1998;274:F79–F90.
[PubMed]
18.
Jerkic M, Miloradovic Z, Jovovic D, Mihailovic-Stanojevic N, Elena JV, Nastic-Miric D, Grujic-Adanja G, Rodriguez-Barbero A, Markovic-Lipkovski J, Vojvodic SB, Manero MV, Prieto MP, Lopez-Novoa JM: Relative roles of endothelin-1 and angiotensin II in experimental post-ischaemic acute renal failure. Nephrol Dial Transplant 2004;19:83–94.
[PubMed]
19.
Kim SJ, Lim YT, Kim BS, Cho SI, Woo JS, Jung JS, Kim YK: Mechanism of reduced GFR in rabbits with ischemic acute renal failure. Ren Fail 2000;22:129–141.
[PubMed]
20.
Deegan PM, Nolan C, Ryan MP, Basinger MA, Jones MM, Hande KR: The role of the renin-angiotensin system in cisplatin nephrotoxicity. Ren Fail 1995;17:665–674.
[PubMed]
21.
Khalil A, Tullus K, Bakhiet M, Burman LG, Jaremko G, Brauner A: Angiotensin II type 1 receptor antagonist (losartan) down-regulates transforming growth factor-β in experimental acute pyelonephritis. J Urol 2000;164:186–191.
[PubMed]
22.
Coux G, Trumper L, Elias MM: Renal function and cortical (Na+,K+-ATPase activity, abundance and distribution after ischaemia-reperfusion in rats. Biochim Biophys Acta 2002;1586:71–80.
[PubMed]
23.
Molinas SM, Trumper L, Serra E, Elias MM: Evolution of renal function and Na+,K+-ATPase expression during ischaemia-reperfusion injury in rat kidney. Mol Cell Biochem 2006;287:33–42.
[PubMed]
24.
Pompermayer K, Souza DG, Lara GG, Silveira KD, Cassali GD, Andrade AA, Bonjardim CA, Passaglio KT, Assreuy J, Cunha FQ, Vieira MA, Teixeira MM: The ATP-sensitive potassium channel blocker glibenclamide prevents renal ischemia/reperfusion injury in rats. Kidney Int 2005;67:1785–1796.
[PubMed]
25.
Schierwagen C, Bylund-Fellenius AC, Lundberg C: Improved method for quantification of tissue PMN accumulation measured by myeloperoxidase activity. J Pharmacol Methods 1990;23:179–186.
[PubMed]
26.
Roe HH, Epstein JH, Goldstein NP: A photometric method for the determination of inulin in plasma and urine. J Biol Chem 1949;178:839–843.
[PubMed]
27.
Ysebaert DK, De Greef KE, Vercauteren SR, Ghielli M, Verpooten GA, Eyskens EJ, De Broe ME: Identification and kinetics of leukocytes after severe ischaemia/reperfusion renal injury. Nephrol Dial Transplant 2000;15:1562–1574.
[PubMed]
28.
Supavekin S, Zhang W, Kucherlapati R, Kaskel FJ, Moore LC, Devarajan P: Differential gene expression following early renal ischemia/reperfusion. Kidney Int 2003;63:1714–1724.
[PubMed]
29.
Sandovici M, Henning RH, van Goor H, Helfrich W, de Zeeuw D, Deelman LE: Systemic gene therapy with interleukin-13 attenuates renal ischemia-reperfusion injury. Kidney Int 2008;73:1364–1373.
[PubMed]
30.
Klahr S, Morrissey J: Angiotensin II and gene expression in the kidney. Am J Kidney Dis 1998;31:171–176.
[PubMed]
31.
Lieberthal W, Koh JS, Levine JS: Necrosis and apoptosis in acute renal failure. Semin Nephrol 1998;18:505–518.
[PubMed]
32.
Donnahoo KK, Shames BD, Harken AH, Meldrum DR: The role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 1999;162:196–203.
[PubMed]
33.
Rabb H, O’Meara YM, Maderna P, Coleman P, Brady HR: Leukocytes, cell adhesion molecules and ischemic acute renal failure. Kidney Int 1997;51:1463–1468.
[PubMed]
34.
Donnahoo KK, Meng X, Ayala A, Cain MP, Harken AH, Meldrum DR: Early kidney TNF-α expression mediates neutrophil infiltration and injury after renal ischemia- reperfusion. Am J Physiol 1999;277:R922–R929.
[PubMed]
35.
Glynne PA, Picot J, Evans TJ: Coexpressed nitric oxide synthase and apical β1 integrins influence tubule cell adhesion after cytokine-induced injury. J Am Soc Nephrol 2001;12:2370–2383.
[PubMed]
36.
Friedewald JJ, Rabb H: Inflammatory cells in ischemic acute renal failure. Kidney Int 2004;66:486–491.
[PubMed]
37.
Lauriat S, Linas SL: The role of neutrophils in acute renal failure. Semin Nephrol 1998;18:498–504.
[PubMed]
38.
Kelly KJ, Williams WW, Colvin RB, Meehan SM, Springer TA, Gutierrez-Ramos JC, Bonventre JV: Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 1996;97:1056–1063.
[PubMed]
39.
Mejia-Vilet JM, Ramirez V, Cruz C, Uribe N, Gamba G, Bobadilla NA: Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am J Physiol Renal Physiol 2007;293:F78–F86.
[PubMed]
40.
Sadoshima J: Novel AT1 receptor-independent functions of losartan. Circ Res 2002;90:754–756.
[PubMed]
41.
Remuzzi G, Perico N, Macia M, Ruggenenti P: The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005;90:S57–S65.
42.
Esteban V, Ruperez M, Vita JR, Lopez ES, Mezzano S, Plaza JJ, Egido J, Ruiz-Ortega M: Effect of simultaneous blockade of AT1 and AT2 receptors on the NF-κB pathway and renal inflammatory response. Kidney Int Suppl 2003;86:S33–S38.
[PubMed]
43.
Fujihara CK, Velho M, Malheiros DM, Zatz R: An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int 2005;67:1913–1924.
[PubMed]
© 2009 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2009
You do not currently have access to this content.
